# Lean Body Mass as a Determinant of Docetaxel Pharmacokinetics and Toxicity

> **NCT01621425** · — · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 25 (actual)

## Conditions studied

- Breast Cancer
- Metastatic Castration-resistant Prostate Carcinoma

## Interventions

- **OTHER:** Lean body mass
- **OTHER:** Total body weight
- **OTHER:** bloodsampling

## Key facts

- **NCT ID:** NCT01621425
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2015-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01621425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01621425, "Lean Body Mass as a Determinant of Docetaxel Pharmacokinetics and Toxicity". Retrieved via MORVS 2026-10-24 from https://api.morvs.ai/clinical/NCT01621425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*